GILD Gilead Sciences Dashboard

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Company profile

Ticker

GILD

Exchange

NASDAQ

Website

www.gilead.com/

CEO

Daniel O'Day

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...

SEC CIK

0000882095

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943047598

GILD stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings

27 Feb 21

Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and fast, with a skew of small and midcap companies releasing their quarterly results.

Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment

22 Feb 21

The following article is sponsored by Lantern Pharma. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

10 Health Care Stocks Showing Unusual Options Activity In Today's Session

19 Feb 21

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.

Gilead Sciences Reports New Partnership With Wake Forest University School Of Divinity To Address HIV Epidemic Through Faith-Based Programming and Community Outreach

16 Feb 21

10 Biggest Price Target Changes For Thursday

11 Feb 21

Press releases

Pro users get this 30m faster

Gilead Sciences to Present at Upcoming Investor Conferences

18 Feb 21

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m.

Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach

16 Feb 21

– Gilead Will Provide $5 Million in Grant Funding to Wake Forest Over 3 Years as Part of the Gilead COMPASS Initiative® in the Southern United States – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a new

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

10 Feb 21

-- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients -- -- Response Rates Observed in New Analysis Remain Consistent

Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

10 Feb 21

Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

8 Feb 21

Calendar

25 Feb 21

28 Feb 21

31 Dec 21

Financial summary

Financial statements Chart GILD financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6B	6B	6B	6B	6B	6B
Cash burn (monthly)	2.3B	469.5M	(positive/no burn)	(positive/no burn)	(positive/no burn)	(positive/no burn)
Cash used (since last report)	4.55B	930.92M	n/a	n/a	n/a	n/a
Cash remaining	1.44B	5.07B	n/a	n/a	n/a	n/a
Runway (months of cash)	0.6	10.8	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

GILD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Feb 21	Brett A Pletcher	Common Stock	Sell	Dispose S	No	Yes	67.41	1,975	133.13K	28,832
10 Feb 21	Wilfong Diane E.	Common Stock	Payment of exercise	Dispose F	No	No	67.29	197	13.26K	17,409
10 Feb 21	Wilfong Diane E.	Common Stock	Option exercise	Aquire M	No	No	0	778	0	17,606
10 Feb 21	Wilfong Diane E.	RSU Common Stock	Option exercise	Dispose M	No	No	0	778	0	15,327
6 Feb 21	Dickinson Andrew D	Common Stock	Payment of exercise	Dispose F	No	No	68.46	538	36.83K	32,543
6 Feb 21	Dickinson Andrew D	Common Stock	Option exercise	Aquire M	No	No	0	1,818	0	33,081
6 Feb 21	Dickinson Andrew D	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,818	0	30,300
6 Feb 21	Brett A Pletcher	Common Stock	Payment of exercise	Dispose F	No	No	68.46	753	51.55K	30,807
6 Feb 21	Brett A Pletcher	Common Stock	Option exercise	Aquire M	No	No	0	2,728	0	31,560
6 Feb 21	Brett A Pletcher	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,728	0	15,824

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

GILD institutional ownership history Ownership history

76.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1475	1499	-1.6%
Opened positions	179	113	+58.4%
Closed positions	203	199	+2.0%
Increased positions	490	584	-16.1%
Reduced positions	663	623	+6.4%

13F shares	Current	Prev Q	Change
Total value	55.92B	60.75B	-7.9%
Total shares	952.21M	961.58M	-1.0%
Total puts	25.87M	25.62M	+1.0%
Total calls	20.87M	19.01M	+9.8%
Total put/call ratio	1.2	1.3	-8.0%

Largest owners	Shares	Value	Change
Capital Research Global Investors	121.67M	$7.09B	+3.9%
BLK Blackrock	111.18M	$6.48B	-5.6%
Vanguard	102.79M	$5.99B	+0.1%
STT State Street	55.21M	$3.22B	-3.1%
Capital International Investors	46.55M	$2.71B	-4.1%
Capital World Investors	38.53M	$2.24B	-2.1%
Geode Capital Management	20.08M	$1.17B	+0.4%
Dodge & Cox	17.11M	$996.71M	+35.7%
NTRS Northern Trust	15.24M	$888.11M	-3.8%
BK Bank Of New York Mellon	13.81M	$804.37M	-16.0%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	111.18M	-6.6M	-5.6%
Capital Research Global Investors	121.67M	+4.56M	+3.9%
Dodge & Cox	17.11M	+4.5M	+35.7%
FMR	3.76M	-3.95M	-51.3%
BK Bank Of New York Mellon	13.81M	-2.63M	-16.0%
Susquehanna International	8.71M	+2.58M	+42.0%
AIG American International	545.7K	-2.17M	-79.9%
BAC Bank Of America	5.33M	-2.03M	-27.5%
Capital International Investors	46.55M	-1.98M	-4.1%
Millennium Management	1.94M	+1.82M	+1580.1%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Taxus Cardium Pharmaceuticals • Spectrum Pharmaceuticals • Idera Pharmaceuticals • Exelixis • Aradigm • Cymabay Therapeutics • Inovio Pharmaceuticals • Viracta Therapeutics • Arena Pharmaceuticals • Ziopharm Oncology

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accredited, ADC, Advisor, advocacy, affiliate, aim, airline, ambition, amid, amplify, Anthony, ASCENT, Asian, assumption, asterisk, autoleucel, barton, biased, Biochemistry, biology, BLA, Black, bluestone, breast, brexucabtagene, Bruton, built, bulevirtide, Cabaret, career, categorized, ceased, celebrate, chaired, Chapter, chargeback, childcare, clear, college, color, comprised, concentrated, conditionally, confirmatory, conjugate, constitute, constituted, constrain, consultation, Consummation, contemplated, contemplating, content, costly, Council, CTA, cultivate, curative, DaVita, deconsolidated, deconsolidation, dedicated, demurrer, diane, digit, disability, distancing, Divinity, Dr, duly, dynamic, earliest, EC, embedded, enjoined, EP, epidermal, equitable, ESG, Eshhar, essential, ethnic, evasion, EVG, evolution, exhibit, family, faster, feedback, female, Fire, Forest, formatted, Forty, freight, gender, genetic, Glaxo, GmbH, gradual, graduate, Grantee, greatest, Gritstone, GTN, HDV, healthier, hepcludex, herewith, Hetero, Hispanic, home, hormone, horning, HR, hub, ICH, Indemnity, inflation, Inline, instance, investor, IOCB, irrevocably, ISABELA, Jacksonville, jacqueline, javier, jeffrey, JMHLW, job, Jounce, jurisdiction, jyseleca, kelly, kevin, KR, kramer, lag, lawfully, lenacapavir, lesser, letter, lieu, lifesaving, Linkbase, listening, lofton, Los, lung, magrolimab, male, Mateo, Mayor, MDS, meaningful, medium, merged, merger, metastatic, misalignment, mission, Missouri, mobilization, moderate, moderately, monthly, morale, mTNBC, myelodysplastic, myeloid, MYR, nonprofit, Nonstatutory, notification, NSCLC, objective, occupancy, omitted, onsite, opt, orientation, Orphan, outbound, outbreak, outpatient, overruled, overruling, pandemic, pathway, pause, physical, physically, Pionyr, Police, postponement, prejudgment, PRIME, race, racial, rapid, ratifying, real, reconfiguration, referenced, refiled, rega, religion, rendered, reoccur, repay, resubstitution, retaliation, reward, richard, RNA, Rodino, rodriguez, route, RPI, sacituzumab, salary, sandra, satisfaction, sBLA, Schema, scheme, School, science, seal, secondary, sense, shelter, signature, Sonoma, split, stead, Stichting, stream, substance, substantive, substitute, substitution, successor, surge, surrogacy, talent, talented, Taxonomy, tecartustm, thereto, thereunto, therewith, thing, thousand, tightened, Title, Tizona, TMFPA, tooth, topoisomerase, tracing, travel, Triangle, tribunal, trodelvy, true, Trustee, TSR, tuition, twelve, tyrosine, unanticipated, unchanged, unconditional, undergraduate, undersigned, unemployment, UnitedHealth, unlawful, Unlimited, unrelated, urgency, urothelial, valuable, variation, veklury, verification, veteran, vi, vii, Vir, virtue, waiting, Wake, Wellcome, whitley, wilfong, willingly, women, workforce, XBRL, Zelig

Removed: AbbVie, absence, ACC, accelerate, accept, advanced, Alameda, allegedly, American, backlog, batch, bill, body, cellular, China, clarification, contamination, copay, cure, Daiichi, deem, discontinuance, DNA, donation, doubtful, elimination, exclude, expedited, explanation, finalization, fit, forming, formulary, governor, harvesting, HIPAA, historically, impair, improving, indefinitely, ingredient, injured, IRS, lessen, LIBOR, limiting, locate, mab, MAGE, magnified, materialize, maturation, Merck, MINE, myeloma, narrow, NASH, neutralizing, nonalcoholic, participating, planned, practical, preceding, produce, prosecution, prospective, provisional, qualify, QUALITATIVE, recruitment, refer, reject, remanded, repatriated, repeal, replaced, replacement, reputational, revision, safer, Sankyo, schedule, selonsertib, sex, stay, suffer, tender, territorial, transparency, Trump, turn, UNRESOLVED, usage, USPTO, vivo, Watson, Writ

From filing 10-K 2020 FY